<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788371</url>
  </required_header>
  <id_info>
    <org_study_id>2011.6</org_study_id>
    <nct_id>NCT01788371</nct_id>
  </id_info>
  <brief_title>Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus</brief_title>
  <official_title>Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing YouAn Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of
      the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with
      high level of HBV DNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Telbivudine and Lamivudine,a preganancy category B medication,reduces HBV DNA and normalizes
      serum ALT in chronic hepatitis B patients with few adverse effects.Two aspects on the drug
      use in pregnancy will be evaluated prospectively in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The data on its tolerability and safety in HBeAg+ pregnant woman with HBV DNA&gt;6log10 copies/Ml during late pregnancy and infants</measure>
    <time_frame>perinatal to 28 weeks after infant delivery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Its efficacy in the reduction of HBV vertical transmission rate</measure>
    <time_frame>perinatal to 28 weeks after infant delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal DNA reduction,ALT normalization, and loss/seroconversion of HBeAg or HBsAg</measure>
    <time_frame>perinatal to 28 weeks of postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Hepatitis B Infection</condition>
  <condition>Chronic Infection</condition>
  <condition>Viremia</condition>
  <arm_group>
    <arm_group_label>No antiviral arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>provide standard of care to mothers and standard immunoprophylaxis to their infants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun</description>
    <arm_group_label>Telbivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum</description>
    <arm_group_label>Lamivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        HBeAg+CHB pregnant woman gestational age 28 weeks HBV-DNA&gt;log10 copies/ml

        Exclusion Criteria:

        co-infection with hepatitis A,C,D,E or HIV evidence of hepatocellular carcinoma
        decompensated liver disease or significant co-morbidity concurrent treatment with
        immune-modulators,cytotoxic drugs,or steroids clinical signs of threatened miscarriage in
        early prenancy evidence of fetal deformity by ultrasound examination the biological father
        of the child had CHB
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing YouAn Hospital</affiliation>
  </overall_official>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing YouAn Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

